Osimertinib plus Selumetinib in EGFR-Mutated Non–Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)

医学 奥西默替尼 塞鲁美替尼 T790米 内科学 肿瘤科 耐受性 不利影响 吉非替尼 胃肠病学 癌症 埃罗替尼 表皮生长因子受体 克拉斯 结直肠癌
作者
James Chih‐Hsin Yang,Yuichiro Ohe,Chao‐Hua Chiu,Xiaoling Ou,Mireille Cantarini,Pasi A. Jänne,Ryan J. Hartmaier,Myung‐Ju Ahn
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:28 (19): 4222-4231 被引量:9
标识
DOI:10.1158/1078-0432.ccr-21-4329
摘要

MEK/ERK inhibition can overcome acquired resistance to osimertinib in preclinical models. Osimertinib (epidermal growth factor receptor [EGFR]-tyrosine kinase inhibitor [TKI]) plus selumetinib (mitogen-activated protein kinase [MEK]1/2 inhibitor) was assessed in the global TATTON study.This multicenter, open-label, Phase 1b study expansion cohort enrolled patients (aged {greater than or equal to}18 years) with advanced MET-negative, EGFRm NSCLC who had progressed on EGFR-TKIs. Patients were assigned to one of two cohorts by prior first-/second-generation [1G/2G] or T790M-directed EGFR-TKI and received osimertinib 80 mg QD and intermittent selumetinib 75 mg BID PO. Safety and tolerability (primary objective) and antitumor activity determined by objective response rate (ORR), and progression-free survival (PFS) using RECIST version 1.1 were assessed. Data cutoff: March 4, 2020.Forty-seven patients received treatment (prior 1G/2G EGFR-TKI, n=12; prior 3G EGFR-TKI, n=35). Forty-four (94%) patients were Asian; 30 (64%) had baseline exon 19 deletion. Most common AEs were diarrhea (89%), decreased appetite (40%), and stomatitis (32%); 11/47 patients (23%) had an AE Grade {greater than or equal to}3 possibly causally selumetinib-related. ORR was 66.7% (95% confidence interval: 34.9-90.1) in the prior 1G/2G EGFR-TKI group, 22.9% (10.4-40.1) in the prior 3G EGFR-TKI group, and 34.0% (2.7-7.2) overall; median PFS was 15.0 (2.7-33.0), 2.8 (1.6-5.5), and 4.2 months (2.7-7.2), respectively.In this small study, AEs and tolerability of osimertinib plus selumetinib were as expected, based on previous studies. The combination demonstrated antitumor activity supportive of further investigation in patients with MET-negative, EGFRm advanced NSCLC, who had progressed on a previous EGFR-TKI.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
墨旱莲完成签到,获得积分10
2秒前
scott_zip发布了新的文献求助10
2秒前
奥利给完成签到,获得积分10
2秒前
明明完成签到 ,获得积分10
3秒前
芹菜自愿内卷完成签到,获得积分10
3秒前
zokor完成签到 ,获得积分0
6秒前
努力退休小博士完成签到 ,获得积分10
7秒前
橙子完成签到,获得积分10
8秒前
陈补天完成签到 ,获得积分10
9秒前
CipherSage应助慧灰huihui采纳,获得10
10秒前
乐观健柏完成签到,获得积分10
11秒前
13秒前
CodeCraft应助大橙子采纳,获得10
13秒前
量子星尘发布了新的文献求助10
14秒前
jeeya完成签到,获得积分10
15秒前
17秒前
科目三应助科研通管家采纳,获得10
17秒前
科目三应助科研通管家采纳,获得10
17秒前
伦语发布了新的文献求助10
17秒前
顾矜应助科研通管家采纳,获得10
17秒前
xuzj应助科研通管家采纳,获得10
17秒前
xuzj应助科研通管家采纳,获得10
17秒前
17秒前
NexusExplorer应助科研通管家采纳,获得10
17秒前
17秒前
17秒前
丘比特应助科研通管家采纳,获得10
18秒前
yull完成签到,获得积分10
18秒前
小巧书雪完成签到,获得积分10
21秒前
大大怪将军完成签到,获得积分10
22秒前
哈哈哈完成签到 ,获得积分0
22秒前
小怪完成签到,获得积分10
23秒前
爱吃泡芙完成签到,获得积分10
24秒前
白桃战士完成签到,获得积分10
25秒前
27秒前
qingchenwuhou完成签到 ,获得积分10
27秒前
XXX完成签到,获得积分10
28秒前
锡嘻完成签到 ,获得积分10
28秒前
29秒前
彗星入梦完成签到 ,获得积分10
29秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038201
求助须知:如何正确求助?哪些是违规求助? 3575940
关于积分的说明 11373987
捐赠科研通 3305747
什么是DOI,文献DOI怎么找? 1819274
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022